Tafasitamab and Lenalidomide Combination Therapy Guide

　　1.Indications and Combination Therapy Guidelines

　　Tafasitamab is approved in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL)who are not eligible for autologous stem cell transplant.This regimen is based on pivotal clinical trial data and is not recommended as monotherapy or for other B-cell lymphoma subtypes unless supported by subsequent clinical evidence.

　　2.Phased Intravenous Infusion and Dosing Schedule

　　The medication is administered via intravenous infusion at a fixed weight-based dose of 12 mg/kg,with a standard 28-day treatment cycle.The dosing frequency transitions from an intensive phase to a maintenance phase to rapidly saturate target receptors and sustain long-term efficacy:

　　Cycle 1:Administered on Days 1,4,8,15,and 22.

　　Cycles 2 and 3:Administered on Days 1,8,15,and 22.

　　Cycle 4 and onwards:Administered only on Days 1 and 15 of each cycle until disease progression or unacceptable toxicity.

　　3.Premedication and Infusion Reaction Monitoring

　　To effectively prevent infusion-related reactions such as fever,chills,and hypotension,a strict premedication regimen must be administered before each infusion.This includes an antipyretic/analgesic(e.g.,acetaminophen),an antihistamine(e.g.,diphenhydramine),and a corticosteroid(e.g.,dexamethasone).Premedication must not be omitted,and patients require close clinical observation for at least 1 hour post-infusion.

　　4.Myelosuppression and Infection Prophylaxis

　　When combined with lenalidomide,the incidence of neutropenia and thrombocytopenia is elevated.Complete blood counts must be monitored weekly.If Grade 3 or higher neutropenia occurs,both drugs should be withheld,and supportive treatment with granulocyte colony-stimulating factor(G-CSF)should be considered until recovery.Prophylactic antiviral therapy for herpes zoster is also highly recommended.

　　5.Core Safety Warnings:Infections and PML Risk

　　The prescribing information carries a Boxed Warning:Tafasitamab may cause or exacerbate serious infections,including opportunistic infections and the rare but fatal progressive multifocal leukoencephalopathy(PML).If a patient develops any new neurological symptoms or cognitive abnormalities during treatment,the medication must be stopped immediately,and an urgent neurological evaluation is required.

　　6.Special Populations and Long-Term Safety Monitoring

　　No initial dose adjustment is required for patients with mild hepatic or renal impairment;safety and efficacy in pediatric patients have not been established.Pregnant women should avoid this drug due to the risk of fetal B-cell depletion,and breastfeeding is contraindicated during treatment and for at least 3 months after the final dose.Some patients may develop anti-drug antibodies;long-term treatment requires continuous monitoring of B-cell recovery and regular viral screenings.